HealthQuill Crohn's Disease
Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor to treat inflammatory bowel disease.
Drugs Health Pharma

Eli Lilly to buy Morphic for $3.2 b in cash to expand integrin therapies

Eli Lilly and Company will acquire biopharmaceutical firm, Morphic Holding Inc., for $3.2 billion in cash, giving it access to a molecule inhibitor.

Read More
Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s disease in adults, have failed to meet the goal of clinical remission.
Drugs Health Pharma

Bristol’s oral drug to treat Crohn’s disease fails remission test

HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.

Read More
Eli Lilly and Company announced its experimental drug for treating severe Crohn's disease met secondary targets in efficacy and safety.
Drugs Health Pharma

Eli Lilly late-stage trial drug for Crohn’s disease meets testing goals

HQ Team October 13, 2023: Eli Lilly and Company announced its experimental drug for treating severe Crohn’s disease met secondary targets in efficacy.

Read More